Argenx to Buy Forte Biosciences for $2.2 Billion
By Adria Calatayud
Argenx said it reached an agreement to buy Forte Biosciences for $2.2 billion, moving to strengthen its immunology pipeline.
European pharmaceutical company Argenx is acquiring Nasdaq-listed Forte for $77 a share in cash, the companies said Monday. The price represents a 41% premium to Forte's closing price on Friday.
Argenx said the deal allows it to add to its pipeline Forte's experimental drug FB102, for which it sees potential to address diseases with high unmet need that have lacked new treatments.
Forte recently reported results of an early-stage clinical trial for the drug that showed a significant treatment benefit in skin condition vitiligo, building on data released last year for another study in celiac disease. Argenx said the drug has potential to address multiple autoimmune diseases.
The boards of both companies have approved the transaction, which is expected to close in the third quarter subject to customary closing conditions, they said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
July 27, 2026 01:36 ET (05:36 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States